High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)

Nancy J. Tarbell, Henry Friedman, William R. Polkinghorn, Torunn Yock, Tianni Zhou, Zhengjia Chen, Peter Burger, Patrick Barnes, Larry Kun

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

Purpose: To compare event-free survival (EFS) in children with high-risk medulloblastoma randomly assigned to receive either chemotherapy before radiation or chemotherapy after radiation. Patients and Methods: One hundred twelve patients were randomly assigned to each arm. Criteria used to categorize patients as high risk included M1-4 disease by modified Chang staging classification, T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery. Postoperatively, children with high-risk medulloblastoma were randomly assigned to two arms, either chemotherapy entailing three cycles of cisplatin and etoposide before radiation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy first [RT1]). Both groups received consolidation chemotherapy consisting of vincristine and cyclophosphamide. Results: The median follow-up time was 6.4 years. Five-year EFS was 66.0% in the CT1 arm and 70.0% in the RT1 arm (P = .54), and 5-year overall survival in the two groups was 73.1% and 76.1%, respectively (P = .47). In the CT1 arm, 40 of the 62 patients with residual disease achieved either complete or partial remission. Conclusion: Five-year EFS did not differ significantly whether, after surgery, patients received chemotherapy before or after radiotherapy.

Original languageEnglish (US)
Pages (from-to)2936-2941
Number of pages6
JournalJournal of Clinical Oncology
Volume31
Issue number23
DOIs
StatePublished - Aug 10 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)'. Together they form a unique fingerprint.

  • Cite this

    Tarbell, N. J., Friedman, H., Polkinghorn, W. R., Yock, T., Zhou, T., Chen, Z., Burger, P., Barnes, P., & Kun, L. (2013). High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). Journal of Clinical Oncology, 31(23), 2936-2941. https://doi.org/10.1200/JCO.2012.43.9984